Loading the session
Loading the session
Loading instrument
$608.49
+1.19%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $608.49 on 4 Nov 2026: 0.9% below the 52-week high of $614.23 (4 Nov 2026) and 37.0% above the low of $444.04 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +12.3% (SPY −1.6%, XLV +13.5%). 3 months: +17.2% (SPY −0.4%, XLV +15.5%). 1 year: +39.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: UTHR, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $608.49 was 14.3% above its 50-day average ($532.33) and 14.0% above its 200-day average ($533.54). It has closed above the 200-day for 26 sessions, since 30 Sep 2026. The 50-day average crossed below the 200-day on 10 Sep 2026, 39 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 72.0 on 4 Nov 2026, its 2nd session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
2.5M shares were sold short at the 15 Oct 2026 settlement, 5.7% of the 42.9M shares outstanding; covering them would take 2.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
September 2, 2025
+32.83%June 10, 2025
−14.32%February 24, 2022
−13.15%